KR20100041363A - A composition comprising fruits of cudrania tricuspidata for immunopotentiating - Google Patents
A composition comprising fruits of cudrania tricuspidata for immunopotentiating Download PDFInfo
- Publication number
- KR20100041363A KR20100041363A KR1020080100512A KR20080100512A KR20100041363A KR 20100041363 A KR20100041363 A KR 20100041363A KR 1020080100512 A KR1020080100512 A KR 1020080100512A KR 20080100512 A KR20080100512 A KR 20080100512A KR 20100041363 A KR20100041363 A KR 20100041363A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- immune function
- diseases
- fruit
- cudrania tricuspidata
- Prior art date
Links
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 77
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 235000010918 Cudrania tricuspidata Nutrition 0.000 title claims abstract description 19
- 241001523380 Maclura tricuspidata Species 0.000 title claims abstract 12
- 230000002434 immunopotentiative effect Effects 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 99
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 230000002708 enhancing effect Effects 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 238000000605 extraction Methods 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000010992 reflux Methods 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 7
- 201000011510 cancer Diseases 0.000 claims abstract description 7
- 206010003645 Atopy Diseases 0.000 claims abstract description 6
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 6
- 208000026935 allergic disease Diseases 0.000 claims abstract description 6
- 206010016256 fatigue Diseases 0.000 claims abstract description 6
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 6
- 238000003809 water extraction Methods 0.000 claims abstract description 5
- 230000006866 deterioration Effects 0.000 claims abstract 3
- 230000036737 immune function Effects 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 235000013402 health food Nutrition 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 6
- 230000001771 impaired effect Effects 0.000 claims description 5
- 238000002137 ultrasound extraction Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 abstract description 21
- 210000004988 splenocyte Anatomy 0.000 abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 44
- 230000000694 effects Effects 0.000 description 28
- 238000002360 preparation method Methods 0.000 description 23
- 241000218211 Maclura Species 0.000 description 22
- 240000000249 Morus alba Species 0.000 description 13
- 235000008708 Morus alba Nutrition 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 240000008067 Cucumis sativus Species 0.000 description 12
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 235000013361 beverage Nutrition 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 244000097654 Cudrania tricuspidata Species 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000010609 cell counting kit-8 assay Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 241000219122 Cucurbita Species 0.000 description 4
- -1 Flavonoid Compounds Chemical class 0.000 description 4
- 244000184734 Pyrus japonica Species 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000013882 gravy Nutrition 0.000 description 3
- 230000005934 immune activation Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 235000015192 vegetable juice Nutrition 0.000 description 3
- IPNPAENNCXAVSJ-UHFFFAOYSA-N 2-[2,4-dihydroxy-5-(3-methylbut-2-enyl)phenyl]-5,7-dihydroxy-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(CC=C(C)C)=CC(C2OC3=C(CC=C(C)C)C(O)=CC(O)=C3C(=O)C2)=C1O IPNPAENNCXAVSJ-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241001107116 Castanospermum australe Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 241000219492 Quercus Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000021279 black bean Nutrition 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 235000008777 kaempferol Nutrition 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WUIDVBXGRNCTFU-UHFFFAOYSA-N 5,7-dihydroxy-2-(7-hydroxy-2,2-dimethylchromen-6-yl)-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one Chemical compound C1=CC(C)(C)OC(C=C2O)=C1C=C2C1CC(=O)C(C(O)=CC(O)=C2CC=C(C)C)=C2O1 WUIDVBXGRNCTFU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 240000007068 Agaricus silvaticus Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 240000000724 Berberis vulgaris Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- XLHAGJGNSIEVFB-UHFFFAOYSA-N euchrestaflavanone B Natural products C1=C(O)C(CC=C(C)C)=CC(C2OC3=CC(O)=C(CC=C(C)C)C(O)=C3C(=O)C2)=C1O XLHAGJGNSIEVFB-UHFFFAOYSA-N 0.000 description 1
- XPMCEWWRVJLSLM-UHFFFAOYSA-N euchrestaflavanone C Natural products C1=CC(C)(C)OC(C=C2O)=C1C=C2C1OC2=CC(O)=C(CC=C(C)C)C(O)=C2C(=O)C1 XPMCEWWRVJLSLM-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 꾸지뽕나무(Cudrania tricuspidata) 열매 추출물을 함유하는 면역기능 강화용 조성물, 꾸지뽕나무 열매 추출물을 함유하는 면역기능 강화용 건강식품, 및 꾸지뽕나무 열매 추출물을 함유하는 면역기능 저하로 인한 질환의 예방 및 치료제에 관한 것이다.The present invention is a composition for strengthening immune function containing Cudrania tricuspidata fruit extract, health food for enhancing immune function containing Cudrania fruit extract, and prevention of diseases caused by lowering immune function containing Cudrania fruit extract And to therapeutic agents.
꾸지뽕나무(Cudrania tricuspidata (Carr.) Bureau ex Lavallee)는 구지뽕나무, 굿가시나무, 활뽕나무 등으로도 불리며 뽕나무과(Moraceae)의 낙엽 활엽 소교목 또는 관목으로 분류된다. 닥나무와 동속의 식물로 원산지는 한국으로 잎은 호생하며 2-3개로 갈라지는 것과 가장자리가 밋밋하고 난형인 것이 있다. 갈라지는 잎은 둔두 원저이며 가장자리가 밋밋한 것은 예두이고 넓은 예저이며 길이 6-10 cm, 너비 3-6 cm로서 표면에 잔털이 있고 뒷면에는 융모가 있다. 엽병은 길이 15-25 mm로서 털이 있다. 잎 모양은 생육장소가 비옥하면 감나무 잎보다 크고 결각도 적으 나 바위틈이나 산비탈의 척박지에서 자라는 것은 잎이 작고 결각이 심하며 잎끝이 꼬리처럼 길게 뻗어난다. 열매는 취과로 둥글며 지름 2.5 cm로서 육질이고 9-10월에 적색으로 성숙하며 수과는 길이 5 mm정도로서 흑색이다. 과육은 달고 식용가능하다(국가생물종지식정보시스템, http://www.nature.go.kr/plant/plantGuide/). 꾸지뽕나무의 항균활성물질로 euchrestaflavanone B와 euchrestaflavanone C가 보고된 바 있으며(이병원, 강남숙, 박기훈. 꾸지뽕나무로부터 항균성 prenylated flavonoids의 분리. 한국응용생명화학회지 제47권 제2호(2004. 6) pp.270-273), 잎 및 목부에서 분리한 kaempferol, kaempferol 7-O-β-D-glucoside, norarthocarpetin, arthocarpesin 등의 과산화 지질 함량 감소 활성에 대한 보고도 있으나 (최종원, 최재수, 박종철. 꾸지뽕나무 잎 , 열매 , 줄기 및 뿌리의 분획물과 플라보노이드 화합물이 흰쥐의 과산화지질 함량에 미치는 영향. 생약학회지, (1995) 26: 377-384) 열매에 대한 유효 활성은 보고된 바 없다. Cudrania tricuspidata (Carr.) Bureau ex Lavallee is also called old mulberry tree, good bark tree, barberry, etc. and is classified as deciduous broad-leaved subtree or shrub of Moraceae. It is a plant of the same type as the mulberry tree, and its origin is Korea, and the leaves are revived, divided into 2-3 pieces, and the edges are flat and ovate. The branching leaves are blunt-headed, the edges are acute, broad-headed, 6-10 cm long, 3-6 cm wide, with fine hairs on the surface, and villi on the back. The petioles are 15-25 mm long and hairy. Leaf shape is bigger than persimmon leaf when the growth place is fertile, and there are fewer cornucopia, but growing in rock cracks or barren slopes has small leaf, severe cornea, and leaf tip extends like tail. Fruits are round, with a diameter of 2.5 cm in diameter, fleshy, mature in red in September-October, and achenes are 5 mm long, black. The flesh is sweet and edible (National Biotechnology Information System, http://www.nature.go.kr/plant/plantGuide/). Euchrestaflavanone B and euchrestaflavanone C have been reported as antimicrobial actives of Cucurbita japonica (Lee Hospital, Kang Sook Park, and Ki Hoon Park. 270-273), but there have been reports of lipid peroxide-reducing activities such as kaempferol, kaempferol 7-O-β-D-glucoside, norarthocarpetin, and arthocarpesin isolated from leaves and necks Effects of Fractions, Flavonoid Compounds, and Flavonoid Compounds on Fruit, Lipid Peroxide Contents in Rats (1995) 26: 377-384) No effective activity has been reported on the fruit.
면역 활성화를 검증하는 대표적인 방법으로 대식세포 증식 효과 (Friedl R, Moeslinger T, Kopp B, and Spiecke- rmann PG. Stimulation of nitric oxide synthesis by the aqueous extract of Panax ginsena root in Raw 264.7 cells. British Journal of pharma- cology, 2001;134:1663-1670.)와 비장세포의 증식 효과를 선택하였다. NO의 생성 촉진 효과는 대식세포 활성화의 지표로 대식세포에서 생성되는 NO는 침입한 병원체를 없애고 기본적인 숙주 방어체계를 작동시키는 역할을 한다(Farrell AJ, Blake DR. Nitric oxide. Annals of the Rheumatic Dieases. 1996;55:7-20.). 특히 Th 세포의 분화단계 중 ThO 상태에서 Thl과 Th2로 나누어질 때, Thl로의 분화를 돕는 작용을 하는 것으로 알려져 있다. 또한 백혈구의 활성 중 암세포, 기생충 또는 박테리아를 살해하는 세포독성 활성은 NO를 유리시킴으로써 나타나는 것으로 보고되고 있다(Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB Journal. 1992;6: 3051-3064.). 또한 기관지 염증에 NO가 T-cell과 내피세포간의 immunomodulating을 하며 (Bingisser RM, Holt PG Immunomodulating mechanism in the lower respiratory tract; nitric oxide mediated intraction between alveolar macrophage, epithelial cell, and T-cell, SWISS Medical Weekly. 2001;131;171-179.) 강력한 혈소판 응집 억제작용이 있다는 것이 알려져 있다. Representative methods of verifying immune activation are macrophage proliferation effects (Friedl R, Moeslinger T, Kopp B, and Spiecke-rmann PG.Stimulation of nitric oxide synthesis by the aqueous extract of Panax ginsena root in Raw 264.7 cells.British Journal of pharma -cology, 2001; 134: 1663-1670.) and the proliferative effects of splenocytes were selected. NO is a marker of macrophage activation. NO produced in macrophages acts to eliminate invading pathogens and activate basic host defenses (Farrell AJ, Blake DR. Nitric oxide. Annals of the Rheumatic Dieases. 1996; 55: 7-20.). Particularly, when Thl and Th2 are divided in the ThO state during the differentiation of Th cells, it is known to have a function of helping to differentiate into Thl. In addition, cytotoxic activity of killing cancer cells, parasites or bacteria among leukocyte activity has been reported to be released by the release of NO (Nathan C. Nitric oxide as a secretory product of mammalian cells.FASEB Journal. 1992; 6: 3051-3064) .). In addition, NO induced immunomodulating between T-cell and endothelial cells (Bingisser RM, Holt PG Immunomodulating mechanism in the lower respiratory tract; nitric oxide mediated intraction between alveolar macrophage, epithelial cell, and T-cell, SWISS Medical Weekly. 2001; 131; 171-179.) It is known that there is a potent platelet aggregation inhibitory effect.
이에 본 발명자들은 꾸지뽕나무 열매 추출물이 비장 세포 및 대식 세포의 증식을 촉진하며, NO의 생성을 유발하며, 생쥐에서 면역감작의 증진에 대해 우수한 효과를 나타내므로 꾸지뽕나무 열매 추출물이 면역 활성화 및 증강 효과가 있음을 확인하므로써 본 발명을 완성하였다.In this regard, the inventors of the present invention, Cucumberberry fruit extract promotes the proliferation of splenocytes and macrophages, induces the production of NO, and exhibits an excellent effect on the enhancement of immune sensitization in mice. By confirming that the present invention was completed.
본 발명의 목적은 꾸지뽕나무(Cudrania tricuspidata) 열매 추출물을 유효성분으로 함유하는 면역기능 강화용 조성물, 꾸지뽕나무 열매 추출물을 유효성분으로 함유하는 면역기능 강화용 건강식품, 및 꾸지뽕나무 열매 추출물을 함유하는 면역기능 저하로 기인한 질환의 예방 및 치료제를 제공하는 것이다.An object of the present invention is a composition for enhancing the immune function containing Cudrania tricuspidata fruit extract as an active ingredient, health food for enhancing the immune function containing the Cudrania fruit extract as an active ingredient, and containing Cucumber fruit extract It is to provide a prophylactic and therapeutic agent for diseases caused by impaired immune function.
본 발명은 꾸지뽕나무(Cudrania tricuspidata) 열매 추출물을 유효성분으로 함유하는 면역기능 강화용 조성물을 제공한다.The present invention provides a composition for enhancing immune function containing Cudrania tricuspidata fruit extract as an active ingredient.
또한, 본 발명은 꾸지뽕나무 열매 추출물을 유효성분으로 함유하는 면역기능 강화용 건강식품을 제공한다.In another aspect, the present invention provides a health food for enhancing immune function containing Cucumber fruit extract as an active ingredient.
또한, 본 발명은 꾸지뽕나무 열매 추출물을 유효성분으로 함유하는 면역기능 저하로 기인하는 질환용 예방 및 치료제를 제공한다.The present invention also provides a prophylactic and therapeutic agent for diseases caused by a decrease in immune function, which contains Cucumber fruit extract as an active ingredient.
아울러, 본 발명은 약학적으로 유효한 양의 꾸지뽕나무 열매 추출물을 개체에 투여하는 단계를 포함하는 면역기능 저하로 인한 질환의 예방 및 치료 방법을 제공한다.In addition, the present invention provides a method for the prevention and treatment of diseases caused by impaired immune function, comprising the step of administering a pharmaceutically effective amount of Cudrania japonica extract to an individual.
본 발명의 꾸지뽕나무 열매 추출물은 생쥐의 비장세포 및 대식 세포의 생장 을 증가시키고, NO의 생성을 증가시키고, 생쥐에서 면역감작의 증진에 대해 우수한 효과를 나타내므로 면역기능의 강화에 효과적이므로, 면역기능 강화용 조성물, 면역기능 강화용 건강식품, 및 면역기능 저하로 기인하는 질환의 예방 및 치료제로 이용하는데 유용하다.Since the extract of the Koji mulberry fruit of the present invention increases the growth of splenocytes and macrophages in mice, increases the production of NO, and shows an excellent effect on the enhancement of immune sensitization in mice, it is effective in enhancing immune function. It is useful for use as a composition for strengthening functions, health foods for enhancing immune function, and as an agent for preventing and treating diseases caused by reduced immune function.
이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 꾸지뽕나무(Cudrania tricuspidata) 열매 추출물을 유효성분으로 함유하는 면역기능 강화용 조성물을 제공한다.The present invention provides a composition for enhancing immune function containing Cudrania tricuspidata fruit extract as an active ingredient.
상기 추출물은 물, 알코올 또는 이들의 혼합물을 용매로 사용하여 추출하는 것이 바람직하나 이에 한정되지 않는다. 상기 저급 알코올은 C1 내지 C4 저급 알코올인 것이 바람직하다. 상기 꾸지뽕나무 열매에 시료 중량의 약 5 내지 20 배, 바람직하게는 약 10배의 물, 저급 알코올 또는 이들의 혼합물을 추출용매로 이용하는 것이 바람직하며, 상기 저급 알코올은 메탄올 또는 에탄올인 것이 바람직하며, 상기 물과 저급 알코올의 혼합물은 10 ~ 90% 메탄올 또는 에탄올 혼합물인 것이 바람직하나 이에 한정되는 것은 아니다. 또한, 실온에서 약 1 내지 24시간, 바람직하게는 4 내지 15시간 동안, 가장 바람직하게는 1 ~ 2시간 동안 추출하는 것이 바람직하나 이에 한정되지 않는다. 추출 방법으로는 열수 추출, 냉침 추출, 환류 냉각 추출, 초음파 추출 및 증기 추출로 이루어진 군으로부터 선택된 어느 하나인 것이 바람직하나 이에 한정되지 않는다. 추출 후 동결건조를 수행하므로써 본 발명의 꾸지뽕나무 열매 추출물을 수득할 수 있다. The extract is preferably extracted using water, alcohol or a mixture thereof as a solvent, but is not limited thereto. It is preferable that the lower alcohol is a C 1 to C 4 lower alcohol. It is preferable to use about 5 to 20 times, preferably about 10 times, water, a lower alcohol, or a mixture thereof as an extractant to the Cucumber fruit, and the lower alcohol is preferably methanol or ethanol, The mixture of water and lower alcohol is preferably 10 to 90% methanol or ethanol mixture, but is not limited thereto. In addition, the extraction is preferably performed at room temperature for about 1 to 24 hours, preferably 4 to 15 hours, most preferably 1 to 2 hours, but is not limited thereto. The extraction method is preferably any one selected from the group consisting of hot water extraction, cold needle extraction, reflux cooling extraction, ultrasonic extraction and steam extraction, but is not limited thereto. By performing lyophilization after extraction, it is possible to obtain the Koji mulberry fruit extract of the present invention.
본 발명자들은 상기와 같이 추출된 꾸지뽕나무 열매 추출물이 생쥐의 비장 세포, 대식 세포의 생장에 미치는 영향을 조사하였다. 그 결과, 비장세포의 증식을 유발하며(표 2 참조), 대식 세포에서도 탁월한 증식 효과를 보이며, 양성 대조군에 비해서도 우월하게 효율적임을 확인하였다(도 1 내지 3 참조). The present inventors investigated the effect of the extract of Koji mulberry fruit extract as described above on the growth of spleen cells, macrophages of mice. As a result, it induces the proliferation of splenocytes (see Table 2), showed an excellent proliferation effect even in macrophages, it was confirmed to be superior to the positive control (see FIGS. 1 to 3).
이후 본 발명자들은 꾸지뽕나무 열매 추출물이 NO 생성에 미치는 영향을 조사하였다. 그 결과, NO 생성 또한 효과적으로 유발하여 면역 증강에 효과적임을 확인하였다(도 4 및 표 3 참조). 아울러 생쥐를 대상으로 하는 면역 감작 증진 효과 또한 뛰어남을 알 수 있었다(도 5 참조). The present inventors then investigated the effect of the kkujimi fruit extract on NO production. As a result, it was confirmed that the production of NO also effective in enhancing the immune (see Fig. 4 and Table 3). In addition, it was also found that the effect of enhancing immune sensitization in mice was also excellent (see FIG. 5).
그러므로 본 발명의 꾸지뽕나무 열매 추출물은 면역기능 강화용 조성물에 효율적으로 이용될 수 있다. Therefore, the Quercus mulberry fruit extract of the present invention can be efficiently used in the composition for enhancing immune function.
본 발명의 면역기능 강화용 조성물은 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 본 발명의 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.The composition for enhancing immune function of the present invention may be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, oral formulations, external preparations, suppositories, and sterile injectable solutions. Carriers, excipients and diluents that may be included in the compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 생약 추출액에 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose ( It is prepared by mixing sucrose or lactose and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. .
비경구 투여를 위한 제제에는 멸균된 수용액, 액제, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제, 주사제제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterile aqueous solutions, solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, suppositories, injections. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
또한, 본 발명은 꾸지뽕나무(Cudrania tricuspidata) 열매 추출물을 유효성분으로 함유하는 면역기능 강화용 건강식품을 제공한다.In addition, the present invention provides a health food for enhancing immune function containing Cudrania tricuspidata fruit extract as an active ingredient.
상기 꾸지뽕나무 열매 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 유제품, 음료, 껌, 차, 비타민 단일제, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다.Examples of the foods to which the Cucumber fruit extract may be added include, for example, various foods, dairy products, beverages, gums, teas, vitamin single agents, health supplements, and the like, powder, granules, tablets, capsules, or beverages. Can be used as
또한, 면역기능 강화를 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 추출물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다. It may also be added to foods or beverages for the purpose of enhancing immune function. At this time, the amount of the extract in the food or beverage can be added in 0.01 to 15% by weight of the total food weight, the health beverage composition is added in a ratio of 0.02 to 5 g, preferably 0.3 to 1 g based on 100 ml Can be.
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 꾸지뽕나무 열매 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 수크로오스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알코올이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The health functional beverage composition of the present invention is not particularly limited to other ingredients except for containing the Cucumberberry extract as essential ingredients in the indicated proportions, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. Can be. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 꾸지뽕나무 열매 추출물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 꾸지뽕나무 열매 추출물은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 꾸지뽕나무 열매 100 중량부 당 0.1 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the ziddonia fruit extract of the present invention is a variety of nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, such as flavoring agents, coloring and neutralizing agents (cheese, chocolate, etc.), pectic acid and salts thereof, Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the Cudrania fruit extract of the present invention may contain a fruit flesh for the production of natural fruit juice and fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The ratio of such additives is not so important but is generally selected from the range of 0.1 to about 20 parts by weight per 100 parts by weight of the kkujiwan fruit of the present invention.
또한, 본 발명은 꾸지뽕나무(Cudrania tricuspidata) 열매 추출물을 유효성분으로 함유하는 면역기능 저하로 인한 질환용 예방 및 치료제를 제공한다.In addition, the present invention provides a preventive and therapeutic agent for diseases caused by reduced immune function containing Cudrania tricuspidata fruit extract as an active ingredient.
상기 면역기능 저하로 기인되는 질환으로는 감기 등의 감염성 질환 및 염증성 질환, 아토피 등의 알러지 질환, 만성피로, 및 암으로 이루어진 군으로부터 선택되는 어느 하나인 것이 바람직하나 이에 한정되는 것은 아니며, 당업자에 알려진 면역기능 저하로 기인되는 질환은 모두 본 발명에 포함된다. 본 발명의 꾸지뽕나무 열매 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 꾸지뽕나무 열매 추출물은 1일 0.0001 내지 500 ㎎/㎏으로, 바람직하게는 0.001 내지 500 ㎎/㎏으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The disease caused by the reduced immune function is preferably any one selected from the group consisting of infectious diseases such as colds and inflammatory diseases, allergic diseases such as atopy, chronic fatigue, and cancer, but is not limited thereto. All diseases resulting from a known decrease in immune function are included in the present invention. Preferred dosages of Cucumberberry extract of the present invention vary depending on the condition and weight of the patient, the extent of disease, drug form, route of administration and duration, and may be appropriately selected by those skilled in the art. However, for the preferred effect, the Cudrania japonica fruit extract of the present invention is preferably administered at 0.0001 to 500 mg / kg, preferably at 0.001 to 500 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
아울러, 본 발명은 약학적으로 유효한 양의 꾸지뽕나무 열매 추출물을 개체에 투여하는 단계를 포함하는 면역기능 저하로 인한 질환의 예방 및 치료방법을 제공한다.In addition, the present invention provides a method for the prevention and treatment of diseases caused by impaired immune function comprising the step of administering a pharmaceutically effective amount of kkujipan fruit extract to a subject.
상기 방법에 있어서, 본 발명의 꾸지뽕나무 열매 추출물은 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내(intracerebroventricular) 주사에 의해 투여될 수 있다. In the above method, the Quercus mulberry fruit extract of the present invention can be administered by various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.
이하, 본 발명을 실시예, 실험예 및 제제예에 의하여 상세히 설명한다.Hereinafter, the present invention will be described in detail by Examples, Experimental Examples and Formulation Examples.
단, 하기 실시예, 실험예 및 제제예는 본 발명을 구체적으로 예시하는 것이며, 본 발명의 내용이 실시예, 실험예 및 제제예에 의해 한정되는 것은 아니다.However, the following Examples, Experimental Examples, and Formulation Examples specifically illustrate the present invention, and the content of the present invention is not limited to Examples, Experimental Examples, and Formulation Examples.
<실시예 1> 꾸지뽕나무 열매(<Example 1> Koji mulberry fruit ( Cudraniae fructusCudraniae fructus ) 추출물 제조A) extract manufacturer
<1-1> 꾸지뽕나무 열매 추출물의 제조<1-1> Preparation of Cucurbita Fruit Extract
꾸지뽕나무 열매(중국산)를 약재상(백제당, 대전)에서 구입하여 사용하였다. 약재의 10배(w/v)에 해당하는 추출용매를 사용하였으며, 추출방법으로는 열수 추출법, 70% 에탄올을 용매로 하여 초음파 추출법 및 환류 추출 방법을 이용하여 3가지 추출액을 수득하였다. 각 추출액을 감압 농축한 후 동결건조하여 추출물을 제조하 였다. 각 추출법에 다른 수율은 하기 표 1과 같다. Cuji mulberry fruit (from China) was purchased from the medicinal herb (Baekje-Dang, Daejeon) and used. An extraction solvent corresponding to 10 times (w / v) of the medicinal herb was used, and three extraction solutions were obtained by using an ultrasonic extraction method and a reflux extraction method using hot water extraction method, 70% ethanol as a solvent as an extraction method. Each extract was concentrated under reduced pressure and lyophilized to prepare an extract. Different yields for each extraction method are shown in Table 1 below.
<실험예 1> 생쥐 비장 세포의 세포증식 효과 조사Experimental Example 1 Investigation of Cell Proliferation Effect of Mouse Spleen Cells
7주령의 수컷 C57BL/6 마우스(대한바이오링크, 충북 음성)를 경추탈골 후 비장을 적출하였다. 적출한 비장을 HBSS(Hank's Balanced Salts Modified. Gbico BRL.)로 세척하고 세포 분리 후 원심분리하여 RBC 세포용해 버퍼(lysing buffer, Sigma)로 적혈구를 제거한 후 10% FBS(fetal bovine serum, Gibco BRL.)와 페니실린(penicillin, Gibco BRL.) 및 스트렙토마이신(streptomycin, Gibco BRL.)을 함유하는 RPMI 1640(Hyclone) 배지에 부유시켜 5% CO2, 37℃에서 배양하였다. 상기 <실시예 1>에서 제조된 꾸지뽕나무 열매 열수 추출물(W), 꾸지뽕나무 열매 70% 에탄올 초음파 추출물(ES) 및 꾸지뽕나무 열매 70% 에탄올 환류 추출물(ER)이 비장 세포 증식에 미치는 효과를 검색하기 위하여 96-웰 플레이트(well plate)에 분리 배양한 비장 세포를 5×105 cells/well로 분주하고 꾸지뽕나무 열매 추출물(열수 추출물(W), 70% 에탄올 초음파 추출물(ES) 및 70% 에탄올 환류 추출물(ER))을 2×10-3~1×100 mg/ml 농도로 PBS에 용해하여 첨가하였다. 세포증식 효과에 대한 비교물질로 ConA(Concanavalin A, Sigma Co., U.S.A)와 LPS(lipopolysaccharide, Sigma Co., U.S.A) 2 μg/ml로 각각 사용하였다. 48시간 배양 후 테트라졸리움 염인 CCK-8 kit(Cell Counting Kit-8, Dojindo Laboratories, Tokyo, Japan) 용액을 첨가하여 4시간 더 배양한 다음 ELISA 리더기(Ceres UV 900C, Bio-tech instrument, U.S.A.)를 이용하여 450 nm에서 흡광도를 측정하였다. 대조군 웰(Control well)의 흡광도에 대한 약물첨가 well의 흡광도의 비를 %로 계산하였고, 여러 웰(well)의 평균값을 사용하였다. 계산식은 다음과 같다.Seven-week-old male C57BL / 6 mice (Korean Biolink, Chungbuk Negative) were extracted after the cervical spine bone. The extracted spleens were washed with HBSS (Hank's Balanced Salts Modified.Gbico BRL.), Centrifuged and separated to remove red blood cells with RBC lysing buffer (Sigma), followed by 10% FBS (fetal bovine serum, Gibco BRL. ) And penicillin (penicillin, Gibco BRL.) And streptomycin (streptomycin, Gibco BRL.) And suspended in RPMI 1640 (Hyclone) medium containing and cultured at 5% CO 2 , 37 ℃. Searching for the effects of Cudrania fruit hydrothermal extract (W), Cudrania fruit 70% ethanol ultrasonic extract (ES) and Cudrania fruit 70% ethanol reflux extract (ER) prepared in <Example 1> on spleen cell proliferation The spleen cells separated and cultured in a 96-well plate were divided into 5 × 10 5 cells / well, and the Cucumber Fruit Extract (Hydrogen Extract (W), 70% Ethanol Ultrasonic Extract (ES) and 70% Ethanol) Reflux extract (ER)) was added dissolved in PBS at a concentration of 2 × 10 −3 to 1 × 10 0 mg / ml. As a comparison material for the cell proliferation effect, ConA (Concanavalin A, Sigma Co., USA) and LPS (lipopolysaccharide, Sigma Co., USA) were used as 2 μg / ml, respectively. After 48 hours of incubation, add tetrazolium salt CCK-8 kit (Cell Counting Kit-8, Dojindo Laboratories, Tokyo, Japan) solution, and incubate for 4 hours more. Absorbance at 450 nm was measured. The ratio of the absorbance of drug addition wells to the absorbance of control wells was calculated in% and the average value of several wells was used. The calculation is as follows.
그 결과, 꾸지뽕나무 열매 추출물을 생쥐에서 분리한 비상세포에 건조약재 해당 농도로 2.5 mg/ml로 처리하였을 때 비장세포의 증식효과가 꾸지뽕나무 추출물 W, ES, ER에서 각각 대조군의 1.8배, 2.2배, 2.3배로 증가되었다. 이것은 양성대조군으로 사용한 LPS와 ConA를 2 μg/ml 처리한 경우 대조군의 150 ± 2.70, 198.22 ± 0.93%로 증가한 것으로 나타났으므로 꾸지뽕나무 열매 추출물은 추출법에 따라 약간의 차이가 있으나 모두 면역 증강에 효과적임을 알 수 있다(표 2).As a result, the growth of splenocytes when treated with 2.5 mg / ml of dry medicinal herbs in the emergency cells isolated from mice was 1.8 times, 2.2 and 2.2 times, respectively. 2x, increased 2.3 times. This resulted in an increase of 150 ± 2.70 and 198.22 ± 0.93% of the control group when 2 μg / ml of LPS and ConA were used as the positive control group. It can be seen that (Table 2).
<실험예 2> 생쥐 대식 세포주의 세포 증식 및 NO(nitric oxide) 생성 효과 조사Experimental Example 2 Investigation of Cell Proliferation and NO (nitric Oxide) Formation in Mouse Macrophage Cell Line
<2-1> 생쥐 대식 세포주의 세포 증식 효과 조사<2-1> Investigation of Cell Proliferation in Mouse Macrophage Cell Line
쥐 대식 세포주(Murin macrophage cell line)인 Raw 264.7 세포주를 96-웰 플레이트에 5 × 103 cells/well로 분주하고 꾸지뽕나무 열매 추출물(열수 추출물(W), 70% 에탄올 초음파 추출물(ES) 및 70% 에탄올 환류 추출물(ER))을 1×10-3~1×100 mg/ml 농도로 처리하였다. 비교물질로는 ConA(Sigma Co., U.S.A)와 LPS(Sigma Co., U.S.A) 2 μg/ml로 각각 사용하였다. 48시간 배양 후 테트라졸리움 염인 CCK-8 kit(Cell Counting Kit-8, Dojindo Laboratories, Tokyo, Japan) 용액을 첨가하여 4시간 더 배양한 다음 ELISA 리더기(Ceres UV 900C, Bio-tech instrument, U.S.A.)를 이용하여 450 nm에서 흡광도를 측정하였다. 대조군 웰(Control well)의 흡광도에 대한 약물첨가 well의 흡광도의 비를 %로 계산하였고, 여러 웰(well)의 평균값을 사용하였다. 계산식은 다음과 같다.Raw 264.7 cell line, a Murin macrophage cell line, was dispensed at 5 × 10 3 cells / well in a 96-well plate, and Cucumber Fruit Extract (Hydrogen Extract (W), 70% Ethanol Ultrasonic Extract (ES) and 70) % Ethanol reflux extract (ER)) was treated at a concentration of 1 × 10 −3 to 1 × 10 0 mg / ml. As a comparison material, ConA (Sigma Co., USA) and LPS (Sigma Co., USA) were used at 2 μg / ml, respectively. After 48 hours of incubation, add tetrazolium salt CCK-8 kit (Cell Counting Kit-8, Dojindo Laboratories, Tokyo, Japan) solution, and incubate for 4 hours more. Absorbance at 450 nm was measured. The ratio of the absorbance of drug addition wells to the absorbance of control wells was calculated in% and the average value of several wells was used. The calculation is as follows.
그 결과, 꾸지뽕나무 열매 열수추출물(W), 70% 에탄올 추출물(ES 및 ER) 모두 건조약재 해당량으로 50 μg/ml 농도에서 모두 대조군의 150% 이상, 2500 μg/ml 농도에서 대조군의 200% 이상으로 세포증식 효과가 우수한 것으로 나타났으며, 50 ~ 2500 μg/ml 농도 범위 내에서 농도의존적으로 RAW264.7 세포의 증식을 촉진하는 것으로 나타났다(도 1~3). As a result, the zirconia fruit hot water extract (W) and 70% ethanol extract (ES and ER) were all dried medicinal equivalents at 50 μg / ml concentration, at least 150% of the control group and 200% of the control group at 2500 μg / ml concentration. It was shown that the cell proliferation effect is excellent and to promote the proliferation of RAW264.7 cells in a concentration-dependent range within the concentration range of 50 ~ 2500 μg / ml (Fig. 1 to 3).
<2-2> 생쥐 대식 세포주의 NO 생성 효과 조사<2-2> NO Production Effect of Mouse Macrophage Cell Line
Raw 264.7 세포를 2.5×105 cells/well로 48-웰 플레이트에 분주하여 CO2 배양기 내에서 24시간 배양한 후 양성 대조군으로 LPS를 농도별로 처리하였다. 약물 처리군에는 꾸지뽕나무 열매 추출물(열수 추출물(W), 70% 에탄올 초음파 추출물(ES) 및 70% 에탄올 환류 추출물(ER))을 0.2, 2, 20, 200, 2000 μg/ml 로 처리하고 18시간 배양 후 상층액을 분리하고 NO 생성량을 측정하였다. NO 생성량은 Griess reagent(Promega, U.S.A)를 이용하여 반응시켰으며 535 nm에서 흡광도를 측정하였다.Raw 264.7 cells were aliquoted into 2.5 × 10 5 cells / well in 48-well plates, incubated in CO 2 incubator for 24 hours, and treated with LPS by concentration as a positive control. The drug treatment group was treated with 0.2, 2, 20, 200, 2000 μg / ml of Cucurbita fruit extract (hot water extract (W), 70% ethanol ultrasonic extract (ES) and 70% ethanol reflux extract (ER)) and 18 After time incubation, the supernatant was separated and NO production was measured. NO production was reacted using Griess reagent (Promega, USA) and the absorbance was measured at 535 nm.
그 결과, 꾸지뽕나무 열매의 추출물을 건조약재 해당량으로 5000 μg/ml 농도RAW 264.7 세포에 처리하고 상등액을 수집하여 생성된 NO의 양을 검색한 결과, 열수추출물(W)과 70% 에탄올 초음파 추출물(ES)은 각각 대조군의 111%와 100%로 NO 생성 촉진효과가 나타나지 않았으나 70% 에탄올의 환류 추출물(ER)은 대조군의 146%로 대직세포의 NO 생성을 촉진하는 것으로 나타났다(도 4 및 표 3).As a result, the extract of Koji berries was treated to 5000 μg / ml concentration RAW 264.7 cells with dry medicinal equivalents, and the amount of NO produced by collecting the supernatant was investigated. (ES) showed no NO production promoting effect in 111% and 100% of the control group, respectively, but reflux extract (ER) of 70% ethanol was found to promote NO production of large cells in 146% of the control group (Fig. 4 and table). 3).
<실시예 3> 꾸지뽕나무 열매 추출물의 생체 내 면역 증강 효과 조사Example 3 In Vivo Immunity Enhancement Effect of Cucumber Fruit Extract
<3-1> 면역 감작 및 약물 투여<3-1> Immunosensitization and Drug Administration
6주령의 C57BL/6 mouse(대한방이오링크, 충북 음성)에 ovalbumin (Imject Ovalbumin, Thermo Scientific) + Aluminium(Aluminum hydroxide Gel, Sigma-Aldrich) (100 μg+200 μg/100 μl)을 복강투여 하여 감작시켰다(0일). 투여 10일 후에 다시 ovalbumin + Aluminium 을 복장투여하여 부스팅(boosting)시켰다(10일). 상기 실시예에서 제조된 꾸지뽕나무 열매 추출물은 0일부터 20일간 건조약재 해당량으로 5 g/kg/day로 투여하여 추출법에 따른 효능을 비교하였다. 대조군, OVA군 및 OVA+Al군은 해당량의 증류수를 경구투여 하였다. 동물실험 시작 후 20일에 ether 마취하에 복부를 절개하여 후대정맥에서 채혈하고 비장을 적출하여 이후의 실험에 사용하였다. Ovalbumin (Imject Ovalbumin, Thermo Scientific) + Aluminum (Aluminum hydroxide Gel, Sigma-Aldrich) (100 μg + 200 μg / 100 μl) was intraperitoneally administered to a 6-week-old C57BL / 6 mouse. Sensitized (day 0). After 10 days of administration, ovalbumin + aluminum was boosted by dressing (day 10). Cuji mulberry fruit extract prepared in the above example was administered at 5 g / kg / day as a dry medicinal equivalent amount from 0 to 20 days compared the efficacy according to the extraction method. The control group, OVA group and OVA + Al group were orally administered the corresponding amount of distilled water. 20 days after the start of animal experiments, the abdomen was incision under ether anesthesia, blood was collected from posterior vena cava, and the spleen was extracted and used for subsequent experiments.
<3-2> 분열유발성 효과(mitogen effect) 검색을 위한 비장세포의 증식 검색<3-2> Proliferation of Splenocytes for Search for Mitogen Effect
20일간 꾸지뽕나무 열매 추출물 투여 후 각 투여군 별로 적출한 비장을 HBSS (Hank's Balanced Salts Modified. Gbico BRL.)로 세척하고 세포 분리 후 원심 분리하여 RBC 세포용해 버퍼(lysing buffer, Sigma)로 적혈구를 제거한 후 10% FBS(fetal bovine serum, Gibco BRL.)와 페니실린, 스트렙토마이신을 함유하는 RPMI 1640(Hyclone) 배지에 부유시켜 5% CO2, 37℃에서 배양하였다. 분열유발성 효과(mitogen effect)를 검색하기 위하여 96-웰 플레이트에 분리 배양한 비장 세포를 5×105 cells/well로 분주하고 대조군 웰에는 PBS를, 다른 웰에는 LPS(10 μg/ml), ConA(4 μg/ml), OVA(10 μg/ml)를 처리하였다. 2일간 배양한 후 테트라졸리움 염인 CCK-8 kit로 세포 증식도를 측정하였다. After administration of Cudrania fruit extract for 20 days, the spleens extracted by each group were washed with HBSS (Hank's Balanced Salts Modified.Gbico BRL.), And then separated by centrifugation to remove red blood cells with RBC lysis buffer (Sigma). 10% FBS (fetal bovine serum, Gibco BRL.), Penicillin and streptomycin containing RPMI 1640 (Hyclone) medium containing was incubated at 5% CO 2 , 37 ℃. To detect mitogen effects, splenocytes isolated and cultured in 96-well plates were dispensed at 5 × 10 5 cells / well, PBS in control wells, LPS (10 μg / ml) in other wells, ConA (4 μg / ml), OVA (10 μg / ml) were treated. After culturing for 2 days, the cell proliferation was measured by CCK-8 kit, which is tetrazolium salt.
그 결과, OVA+Aluminium(100 μg + 200 μg/100 μl)을 10일 간격으로 2회 감작한 C57 BL/6 마우스에 꾸지뽕나무 열매 물추출물을 건조약재 해당량으로 5 g/kg/day의 용량으로 3주간 경구 후 비장을 분리하여 분열유발성 효과를 확인한 결과 대조군인 OVA 보다 꾸지뽕나무 열매 투여군(W)의 분열유발성 효과가 우수한 것으로 나타났다(도 5).As a result, the C57 BL / 6 mouse, which was sensitized with OVA + Aluminium (100 μg + 200 μg / 100 μl) twice at 10 days intervals, was used as a dry medicinal equivalent with 5 g / kg / day As a result of separating oral spleen after 3 weeks and confirming the cleavage-induced effect, the cleavage-inducing effect of the control group (W) was higher than the control group OVA (Fig. 5).
상기 결과를 통해 본 발명의 꾸지뽕나무 열매의 열수추출물, 70% 에탄올 추출물이 모두 생쥐 비장세포의 세포증식, 대식세포의 증식, 대식세포의 NO 생성 촉진, 생쥐에서 면역감작의 증진에 대해 우수한 효과를 나타냈으므로 본 발명에서는 꾸지뽕나무는 면역 활성화 및 면역 기능 강화에 사용될 수 있음을 제시한다.Through the above results, both the hot water extract and the 70% ethanol extract of the Koji mulberry fruit of the present invention have excellent effects on the cell proliferation of mouse splenocytes, the proliferation of macrophages, the promotion of NO production of macrophages, and the enhancement of immune sensitization in mice. As shown, the present invention suggests that the Cudrania tree can be used for immune activation and immune function enhancement.
하기에 본 발명의 조성물을 위한 제제예를 예시한다.Examples of formulations for the composition of the present invention are illustrated below.
<제제예 1> 약학적 제제의 제조Preparation Example 1 Preparation of Pharmaceutical Formulation
<1-1> 산제의 제조 <1-1> Preparation of Powder
본 발명의 꾸지뽕나무 열매 물 추출물 2 gCudrania fruit water extract 2 g of the present invention
유당 1 g1 g lactose
상기의 성분을 혼합한 후, 기밀포에 충진하여 산제를 제조하였다.After mixing the above components, the airtight cloth was filled to prepare a powder.
<1-2> 정제의 제조 <1-2> Preparation of Tablet
본 발명에 따른 꾸지뽕나무 열매 70% 에탄올 추출물(ES) 100 ㎎Cudrania fruit 70% ethanol extract (ES) according to the
옥수수전분 100 ㎎
유 당 100 ㎎
스테아린산 마그네슘 2 ㎎2 mg magnesium stearate
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
<1-3> 캡슐제의 제조 <1-3> Preparation of Capsule
본 발명의 꾸지뽕나무 열매 70% 에탄올 추출물(ER) 100 ㎎Cudrania fruit 70% ethanol extract of the present invention (ER) 100 mg
옥수수전분 100 ㎎
유 당 100 ㎎
스테아린산 마그네슘 2 ㎎2 mg magnesium stearate
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
<1-4> 주사액제의 제조 <1-4> Preparation of Injection Solution
본 발명에 따른 꾸지뽕나무 열매 물 추출물 10 ㎍/㎖Cudrania fruit water extract 10 ㎍ / ㎖ according to the present invention
묽은 염산 BP pH 3.5로 될 때까지Dilute hydrochloric acid BP until pH 3.5
주사용 염화나트륨 BP 최대 1 ㎖Injectable sodium chloride BP up to 1 ml
적당한 용적의 주사용 염화나트륨 BP 중에 본 발명에 따른 목이버섯 균사체 분말을 용해시키고, 생성된 용액의 pH를 묽은 염산 BP를 사용하여 pH 3.5로 조절하고, 주사용 염화나트륨 BP를 사용하여 용적을 조절하고 충분히 혼합하였다. 용액을 투명 유리로 된 5 ㎖ 타입 I 앰플 중에 충전시키고, 유리를 용해시킴으로써 공기의 상부 격자하에 봉입시키고, 120 ℃에서 15 분 이상 오토클래이브시켜 살균하여 주사액제를 제조하였다.Dissolve the wood mushroom mycelium powder according to the present invention in an appropriate volume of sodium chloride BP for injection, adjust the pH of the resulting solution to pH 3.5 with dilute hydrochloric acid BP, and adjust the volume with sodium chloride BP for injection and sufficiently Mixed. The solution was filled into a 5 ml Type I ampoule made of clear glass, encapsulated under an upper grid of air by dissolving the glass, and sterilized by autoclaving at 120 ° C. for at least 15 minutes to prepare an injection solution.
<제제예 2> 식품의 제조Preparation Example 2 Preparation of Food
본 발명에 따른 본 발명의 꾸지뽕나무 열매 추출물을 포함하는 식품들을 다음과 같이 제조하였다.Foods containing Cucumber fruit extract of the present invention according to the present invention were prepared as follows.
<2-1> 밀가루 식품의 제조 <2-1> Preparation of Flour Food
본 발명의 꾸지뽕나무 열매 물 추출물 0.1 ~ 10.0 중량부를 밀가루에 첨가하고, 이 혼합물을 이용하여 통상의 방법으로 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.0.1 ~ 10.0 parts by weight of the extract of Kokjiberry fruit water of the present invention was added to flour, and bread, cake, cookies, crackers and noodles were prepared in a conventional manner using this mixture to prepare foods for health promotion.
<2-2> 스프 및 육즙(gravies)의 제조 <2-2> Preparation of Soups and Gravys
본 발명의 꾸지뽕나무 열매 물 추출물 0.1 ~ 1.0 중량부를 스프 및 육즙에 첨가하여 통상의 방법으로 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.0.1 ~ 1.0 parts by weight of the extract of Cudrania fruit water of the present invention was added to soup and gravy to prepare meat products for health promotion, soup and gravy of noodles in a conventional manner.
<2-3> 그라운드 비프(ground beef)의 제조 <2-3> Preparation of Ground Beef
본 발명의 꾸지뽕나무 열매 물 추출물 10 중량부를 그라운드 비프에 첨가하여 통상의 방법으로 건강 증진용 그라운드 비프를 제조하였다.10 parts by weight of the extract of Kokji berry fruit water of the present invention was added to the ground beef to prepare ground beef for health promotion in a conventional manner.
<2-4> 유제품(dairy products)의 제조 <2-4> Production of Dairy Products
본 발명의 꾸지뽕나무 열매 물 추출물 0.1 ~ 1.0 중량부를 우유에 첨가하고, 상기 우유를 이용하여 통상의 방법으로 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.0.1 ~ 1.0 parts by weight of the extract of Cudrania fruit water of the present invention was added to milk, and various dairy products such as butter and ice cream were prepared in a conventional manner using the milk.
<2-5> 선식의 제조 <2-5> Preparation of Wire
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted to prepare a powder having a particle size of 60 mesh.
검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Black beans, black sesame seeds, and perilla were also steamed and dried by a known method, and then ground to a powder having a particle size of 60 mesh.
본 발명의 꾸지뽕나무 열매 물 추출물을 진공 농축기에서 감압, 농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다.The dried Cucumber fruit water extract of the present invention was decompressed and concentrated in a vacuum concentrator, dried by spraying and a hot air dryer, and then pulverized to 60 mesh in a particle size with a grinder to obtain a dry powder.
상기에서 제조한 곡물류, 종실류 및 본 발명에 따른 목이버섯 균사체 분말을 다음의 비율로 배합하여 통상의 방법으로 제조하였다.The grains, seeds and the mycelium mycelium mycelium powder according to the present invention were prepared in the following ratio to prepare a conventional method.
곡물류(현미 30 중량부, 율무 15 중량부, 보리 20 중량부),Cereals (30 parts by weight brown rice, 15 parts by weight brittle, 20 parts by weight of barley),
종실류(들깨 7 중량부, 검정콩 8 중량부, 검정깨 7 중량부),Seeds (7 parts by weight perilla, 8 parts by weight black beans, 7 parts by weight black sesame seeds),
본 발명의 꾸지뽕나무 열매 물 추출물(1 중량부),Cudrania fruit water extract of the present invention (1 part by weight),
영지(0.5 중량부),Ganoderma lucidum (0.5 parts by weight),
지황(0.5 중량부)Foxglove (0.5 part by weight)
<제제예 3> 음료의 제조Preparation Example 3 Preparation of Beverage
본 발명의 꾸지뽕나무 열매 물 추출물을 포함하는 음료를 다음과 같이 제조하였다.Drinks containing the extract of the Koji fruit tree of the present invention was prepared as follows.
<3-1> 건강음료의 제조 <3-1> Preparation of Health Beverage
액상과당(0.5%), 올리고당(2%), 설탕(2%), 식염(0.5%), 물(75%)과 같은 부재료와 본 발명에 따른 꾸지뽕나무 열매 물 추출물을 균질하게 배합하여 순간 살균을 한 후, 이를 유리병, 패트병 등 소포장 용기에 포장하여 건강음료를 제조하였다.Instant sterilization by homogeneously mixing subsidiary materials such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%), water (75%) and the extract of Cucurbita fruit according to the present invention. After this, it was packaged in a small packaging container such as glass bottles, plastic bottles to prepare a healthy beverage.
<3-2> 야채쥬스의 제조 <3-2> Preparation of Vegetable Juice
본 발명의 꾸지뽕나무 열매 물 추출물 0.5 g을 토마토 또는 당근 등의 야채의 쥬스 1,000 ㎖에 가하여 통상의 방법으로 건강 증진용 야채쥬스를 제조하였다.0.5 g of Cudrania fruit water extract of the present invention was added to 1,000 ml of a vegetable juice such as tomato or carrot to prepare a vegetable juice for health promotion in a conventional manner.
<3-3> 과일쥬스의 제조 <3-3> Preparation of Fruit Juice
본 발명의 꾸지뽕나무 열매 물 추출물 0.1 g을 사과 또는 포도 등의 과일의 쥬스 1,000 ㎖에 가하여 통상의 방법으로 건강 증진용 과일쥬스를 제조하였다.0.1 g of Cudrania fruit water extract of the present invention was added to 1,000 ml of fruit such as apple or grape to prepare fruit juice for health promotion in a conventional manner.
본 발명의 꾸지뽕나무 열매 추출물은 면역 활성화 및 증강 효과가 있으므로, 면역기능 강화용 조성물, 면역기능 강화용 건강식품, 및 감염성 질환 및 염증성 질환, 아토피 등의 알러지 질환, 만성피로, 및 암 등의 면역기능 저하로 인한 질환의 예방 및 치료제로 유용하게 이용될 수 있다. Since the extract of Cudrania japonica of the present invention has an immune activation and augmentation effect, the composition for enhancing immune function, health food for enhancing immune function, and allergic diseases such as infectious diseases and inflammatory diseases, atopy, chronic fatigue, and cancer It can be usefully used as a prophylactic and therapeutic agent for diseases caused by reduced function.
도 1은 생쥐 대식세포에서 본 발명의 꾸지뽕나무 열매 열수 추출물(W) 처리에 따른 대식세포의 증식 효과를 나타내는 그래프이다.Figure 1 is a graph showing the proliferation effect of macrophages according to the treatment of kkujija fruit hot water extract (W) of the present invention in mouse macrophages.
도 2은 생쥐 대식세포에서 본 발명의 꾸지뽕나무 열매 70% 에탄올 초음파 추출물(ES) 처리에 따른 대식세포의 증식 효과를 나타내는 그래프이다.Figure 2 is a graph showing the proliferation effect of macrophages according to the treatment of the Cudrania fruit 70% ethanol ultrasonic extract (ES) of the present invention in mouse macrophages.
도 3은 생쥐 대식세포에서 본 발명의 꾸지뽕나무 열매 70% 에탄올 환류 추출물(ER) 처리에 따른 대식세포의 증식 효과를 나타내는 그래프이다.Figure 3 is a graph showing the proliferation effect of macrophages according to the treatment of kkujija fruit 70% ethanol reflux extract (ER) of the present invention in mouse macrophages.
도 4는 생쥐 대식세포주에서 본 발명의 꾸지뽕나무 열매 추출물 처리에 따른 NO 생성 유발 효과를 나타내는 그래프이다. Figure 4 is a graph showing the NO production inducing effect according to the treatment of Koji mulberry fruit extract of the present invention in mouse macrophage line.
도 5는 OVA + Al 감작 생쥐에서 꾸지뽕나무 열매 열수 추출물의 분열유발성 효과(mitogen effect)를 나타내는 그래프이다.FIG. 5 is a graph showing the mitogen effect of the Fiji mulberry fruit hydrothermal extract in OVA + Al sensitized mice.
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080100512A KR101045031B1 (en) | 2008-10-14 | 2008-10-14 | A composition comprising fruits of Cudrania tricuspidata for immunopotentiating |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080100512A KR101045031B1 (en) | 2008-10-14 | 2008-10-14 | A composition comprising fruits of Cudrania tricuspidata for immunopotentiating |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100041363A true KR20100041363A (en) | 2010-04-22 |
KR101045031B1 KR101045031B1 (en) | 2011-06-30 |
Family
ID=42217118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080100512A KR101045031B1 (en) | 2008-10-14 | 2008-10-14 | A composition comprising fruits of Cudrania tricuspidata for immunopotentiating |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101045031B1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102117520B1 (en) * | 2019-09-24 | 2020-06-03 | (주)한생플래닛 | Composition for improving or treating atopic dermatitis comprising extracts of a mulberry tree as active ingredient |
KR20200092185A (en) * | 2019-01-24 | 2020-08-03 | 대구한의대학교산학협력단 | Composition containing the glycoprotein isolated from Cudrania tricuspidata Bureau in the stimulation of the proliferation and cycle of intestinal epithelial cells |
KR102141337B1 (en) * | 2020-05-25 | 2020-08-04 | 주식회사 한생플래닛 | Functional food having composition for prevention and treatment atopic dermatitis comprising extracts of a mulberry tree as active ingredient |
KR102141148B1 (en) * | 2020-05-25 | 2020-08-05 | (주)한생플래닛 | Cosmetic composition having composition for prevention and treatment atopic dermatitis comprising extracts of a mulberry tree as active ingredient |
KR20220158881A (en) * | 2021-05-24 | 2022-12-02 | 극동대학교 산학협력단 | Composition comprising Euchrestaflavone B for prevention or treatment of thrombotic disorders |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230006133A (en) | 2021-07-02 | 2023-01-10 | 재단법인 경남한방항노화연구원 | Cosmetic composition having skin whitening effect comprising compounds from fruits of Cudrania tricuspidata |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5061557B2 (en) * | 2006-09-27 | 2012-10-31 | マツダ株式会社 | Automotive bumper structure |
-
2008
- 2008-10-14 KR KR1020080100512A patent/KR101045031B1/en active IP Right Grant
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200092185A (en) * | 2019-01-24 | 2020-08-03 | 대구한의대학교산학협력단 | Composition containing the glycoprotein isolated from Cudrania tricuspidata Bureau in the stimulation of the proliferation and cycle of intestinal epithelial cells |
KR102117520B1 (en) * | 2019-09-24 | 2020-06-03 | (주)한생플래닛 | Composition for improving or treating atopic dermatitis comprising extracts of a mulberry tree as active ingredient |
KR102141337B1 (en) * | 2020-05-25 | 2020-08-04 | 주식회사 한생플래닛 | Functional food having composition for prevention and treatment atopic dermatitis comprising extracts of a mulberry tree as active ingredient |
KR102141148B1 (en) * | 2020-05-25 | 2020-08-05 | (주)한생플래닛 | Cosmetic composition having composition for prevention and treatment atopic dermatitis comprising extracts of a mulberry tree as active ingredient |
KR20220158881A (en) * | 2021-05-24 | 2022-12-02 | 극동대학교 산학협력단 | Composition comprising Euchrestaflavone B for prevention or treatment of thrombotic disorders |
Also Published As
Publication number | Publication date |
---|---|
KR101045031B1 (en) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101160943B1 (en) | Health functional foods compositions for the prevention and amelioration of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient | |
KR101613693B1 (en) | Composition for Prevention or Treatment of Skin Disease Comprising an Extract of Sargassum Horneri and Method of Preparing The Same | |
KR101045031B1 (en) | A composition comprising fruits of Cudrania tricuspidata for immunopotentiating | |
KR101484021B1 (en) | A Composition Comprising the extract of combined herbs including Curcuma Longa L. for immuno-stimulating activity | |
KR101039110B1 (en) | A water composition comprising Broussonetia kazinoki Sieb. for immunopotentiating | |
KR100597235B1 (en) | Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis | |
KR20140017932A (en) | Composition of diabetes-improving effective constituents by fermentation products of the trifoliate orange | |
JP5409439B2 (en) | Composition for enhancing immune function, comprising Kouzo extract | |
KR100824970B1 (en) | Polygoni cuspidati radix extract for allergic disease and process for preparation thereof | |
KR100921909B1 (en) | Composition of healthy food comprising butanol solvent extract of Codonopsis lanceolata Benth et Hook having hematopoietic stem cell proliferation activity | |
KR101018403B1 (en) | composition comprising the extract of soybean leaves for the prevention?delay or treatment of gout | |
KR20140129492A (en) | Compositions Comprising a Leaf Extract of Cudrania tricuspidata for the Prevention and Treatment of Arthritis disease | |
KR101207239B1 (en) | A composition for the prevention and treatment of inflammatory disease comprising the fractions of Asparagus cochinchinensis as an active ingredient | |
KR101503352B1 (en) | A composition for skin protection including skin aging, anti-inflammatory comprising the extracts of Lactarius hatsudake as an active ingredients | |
KR101033003B1 (en) | A composition comprising Broussonetiae Fructus for immunopotentiating | |
KR101044717B1 (en) | Composition containing extract of soybean leaves for prevention, delay or treatment of diabetes | |
KR101862282B1 (en) | A Composition Comprising the combined herbal extract of Dendropanax morbifera and Acanthopanax senticosus HARMS for immuno-stimulating activity | |
KR100750873B1 (en) | A pharmaceutical composition comprising the extract of Rubiae Radix for treating or preventing allergic disease | |
KR101257909B1 (en) | Pharmaceurtical compositions for the prevention or treatment of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient | |
KR102270923B1 (en) | Composition for improving immunity including fermented blueberry and black rice extracts | |
KR101712889B1 (en) | Pharmaceutical composition comprising Zingiber mioga extracts or its fractions for prevention and treatment of neurodegenerative disorders as an active ingredient | |
KR101624293B1 (en) | Composition for enhancing immune response comprising extract of Benincasa hispida Cogniaux or fermented extract of the same | |
KR101904819B1 (en) | Composition comprising Fermented Momordica charantia L. and Allium sativum L. using Amyloliquefaciens Bacillus Jis-1 for lowering blood glucose or preventing and treating diabetes mellitus | |
KR101402599B1 (en) | Composition comprising saussurea pulchella fisch for preventing and treating allergy disease | |
KR100757220B1 (en) | Composition comprising the extract of salicis radicis cortex for immune activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131001 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160622 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170412 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20181008 Year of fee payment: 8 |